Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Add filters

Year range
International Journal of Traditional Chinese Medicine ; (6): 517-521, 2018.
Article in Chinese | WPRIM | ID: wpr-693639


Objective To analyze the treatment and medication rules of formulae containing prepared rehmannia root in Pharmaceutical Standard of Ministry of Public Health of the People's Republic of China-Traditional Chinese Patent Medicine (referred to as Traditional Chinese Patent Medicine). Methods Through Traditional Chinese Medicine Inheritance Support Platform (V2.5), prescriptions containing prepared rehmannia root in traditional Chinese patent medicine were selected and collected to build the database. Frequency counts,association rules and other data mining methods were used to analyze the frequency of indication syndromes and medicine combination of prescription containing prepared rehmannia root, and the compatibility rule of high frequency drug pairs and the rescription rule of core syndromes were analyzed. Results There were a total of 467 prescriptions containing pepared rehmannia root, involving 28 combinations of commonly used Chinese herbals (support degree 30%). The compatibility source of high-frequency drug pairs of prepared rehmannia root and Angelicae Sinensis, prepared rehmannia root and Astragalus embranaceus were both of Shiquan-Dabu decoction in Taiping Huimin Heji Ju Fang (support degree 40%). There were a total of 81 indication syndromes, and among them, there were 16 kinds of high-frequency indication syndromes (the frequency greater than or equal to 10). The core drug combination of high-frequency indication syndromes of "deficiency of both qi and blood" (137 times) and "deficiency of kidney yang" (63 times) were the subtract of Shiquan-Dabu decoction and Yougui pill in Jingyue Quanshu respectively. Conclusions Prepared rehmannia root is mainly compatible with herbs of nourishing blood, supplementing qi and invigorating yang in the traditional Chinese patent medicine containing prepared rehmannia root. The traditional Chinese patent medicine containing prepared rehmannia root were based mainly on classical prescriptions. This study can provide reference for clinical application and new drug development of pepared rehmannia root.

China Pharmacy ; (12): 2813-2816, 2018.
Article in Chinese | WPRIM | ID: wpr-704894


OBJECTIVE:To provide reference for clinical application and related new drug R&D of the couplet medicines of Platycodon grandiflorum-Glycyrrhiza uralensis. METHODS:All set prescription preparations containing P. grandiflorum-G. uralensis in Ministry of Public Health Drug Standard·TCM Set Prescription Preparation were collected;data mining and analysis for the syndrome and treatment rules of these prescriptions were performed by using TCM Inheritance System V 2.5. RESULTS:There were a total of 315 set prescription preparations containing couplet medicine of P. grandiflorum-G. uralensis , 89 main syndromes and 88 main diseases. Among of them,high frequency major syndrome were exterior syndrome attacked by wind-heat and exterior syndrome tightened by wind-cold,and dominating medicine combination were respectively Yinqiao powder and Xingsu powder. High frequency main diseases were common cold and cough. Core medicine combination in the treatment of common cold included Yinqiao powder, Xingsu powder,Huoxiang zhengqi powder and Chaihu zhijie decoction,etc. Core medicine combination in the treatment of cough included Xingsu powder,Zhisou powder,Tongxuan lifei pills and Qingjin huatan decoction,etc. CONCLUSIONS:The study confirms the syndrome and treatment rules of set prescription preparations containing couplet medicines of P. grandiflorum-G. uralensis , and could provide evidence for clinical application of the couplet medicines of P. grandiflorum-G. uralensis and new drug R&D.

World Science and Technology-Modernization of Traditional Chinese Medicine ; (12): 801-805, 2014.
Article in Chinese | WPRIM | ID: wpr-447404


This study was aimed to observe the protective effect of extract from Rhizoma A nemones Raddeanae (RAR) on hepatic fibrosis induced by porcine serum in rats. A total of 68 SD rats were randomly divided into 5 groups, which were the normal group, model group, RAR group, extraction of RAR (EXRAR) group, Fu-Zheng Hua-Y u(FZHY) group. Each rat was intraperitoneally injected with 0.5~0.6 ml of porcine serum twice a week for 15 suc-cessive weeks to establish liver fibrosis model. Intragastric administration was given after the model was successfully established. The FZHY group was given FZHY capsule (0.525 g·kg-1). The RAR group was given RAR decoction (0.7 g·kg-1). The EXRAR group was given EXRAR (0.071 g·kg-1). The model group and normal group were given e-qual amount of physiological saline. The medication was given once a day. And the treatment course was 8 weeks. At the end of the 23th week, rats were sacrificed. Contents of SOD and MDA in blood serum were assayed. The protein expressions of α-SMA and TGF-β1 in liver tissues were detected by SABC. The results showed that compared with the model group, content of MDA decreased in the EXRAR group, RAR group and FZHY group (P<0.05), and content of SOD increased obviously (P<0.05). In the model group, expression of α-SMA and TGF-β1 increased, with dark brown dyeing and diffusion area. Expression area and strength of the FZHY group, RAR group, and EXRAR group were ob-viously weak with tasteless interval dyeing and no formation of typical pseudolobule in comparison with the model group. The color rendering index showed that compared with the model group, the protein expression of α-SMA and TGF-β1 decreased obviously in liver tissues of the FZHY group, EXRAR group, and RAR group (P< 0.05). It was concluded that RAR and its extract had a good antifibrosis effect. And the EXRAR had basically the same antifibrosis effect as RAR. It was assumed that the possible mechanism was related with the inhibiting of hepatic stellate cell (HSC) activation and the expression of TGF-β1 as well as the resisting of lipid peroxidation.

Chinese Journal of Infection and Chemotherapy ; (6): 323-326, 2014.
Article in Chinese | WPRIM | ID: wpr-455022


Objective To investigate the distribution and antimicrobial resistance in Enterococcus species isolated from Ordos Central Hospital.Methods The Enterococcus strains were isolated from clinical specimens from January 2010 to June 2013.The identification and antimicrobial susceptibility testing were completed on VITEK 2 Compact.WHONET 5.6 software was used to analyze the data.Results A total of 271 strains of Enterococcus were collected,including E.faecium (50.6%,137/271), E.faecalis (29.5%,80/271),and other Enterococcus (19.9%,54/271).The Enterococcus isolates were mainly from urine (25.5%,69/271 ),pus (14.8%,40/271 )and wound secretion (12.5%,34/271 ).The E.faecalis strains were highly susceptible to vancomycin and linezolid.Only 1 .3% and 1 .5% of the strains were resistant to vancomycin and linezolid, respectively.No strains of E.faecalis were resistant to nitrofurantoin.The percentage of E.faecalis resistant to penicillin and ampicillin was 11.8% and 2.6%,respectively.About 31.0% and 22.9% of E.faecalis strains were resistant to gentamicin (high level)and streptomycin (high level),respectively.The E.faecium strains were more resistant to most antibiotics tested than E.faecalis.The drug-resistance rate of E.faecium strains to vancomycin was 4.4%.But no strains were found resistant to linezolid.Only 19.1% of these strains were resistant to nitrofurantoin.Also 44.8% and 26.4% of E. faecium isolates were resistant to gentamicin (high level)and streptomycin (high level),respectively.However,E.faecium was less resistant to tetracycline and quinupristin-dalfopristin than E.faecalis.The resistance rate was 58.3% and 0, respectively.Conclusions The E.faecium strains are more resistant to most drugs tested than E.faecalis.Some strains are resistant to vancomycin.The resistance of Enterococcus varies widely with region and species.Antimicrobial therapy for such enterococcal infections should be based on the results of antimicrobial susceptibility testing.